FAP and neoplasm: The biodistribution data of mice co-injected with natGa-FAPI-04 (0.5 mg/mouse) revealed a ~96% reduction in the tumor uptake and further substantiated the in vivo FAP specificity of our lead candidate [68Ga]Ga-SB03045.